Paper
78
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer
Authors
Andrew N.J. Tutt,Judy E. Garber
Bella Kaufman,Giuseppe Viale,Debora Fumagalli,Priya Rastogi,Richard D. Gelber,Evandro de Azambuja,Anitra Fielding,Judith Balmaña,Susan M. Domchek,Karen A. Gelmon,Simon J. Hollingsworth,Larissa A. Korde,Barbro Linderholm,Hanna Bandos,Elżbieta Senkus,Jennifer M. Suga,Zhimin Shao,Andrew W. Pippas,Zbigniew Nowecki,Tomasz Huzarski,Patricia A. Ganz,Peter C. Lucas,Nigel Baker,Sibylle Loibl,Robin McConnell,Martine Piccart,Rita Schmutzler,Guenther G. Steger,Joseph P. Costantino,Amal Arahmani,Norman Wolmark,Eleanor McFadden,Vassiliki Karantza,Sunil R. Lakhani,Greg Yothers,Christine Campbell,Charles E. Geyer,Andrew Tutt,Judy Garber,Richard Gelber,Evandro Azambuja,A.L. Granados,Susan Domchek,Karen Gelmon,Simon Hollingsworth,Larissa Korde,Jennifer Suga,Andrew Pippas,Patricia Ganz,Peter Lucas,David O’Malley,Guenther Steger,Jos Jonkers,Sunil Lakhani
+54 authors
,Charles GeyerPublished
Jun 3, 2021
Show more
Save
Tip78
TipSave
Abstract
Poly(adenosine diphosphate–ribose) polymerase inhibitors target cancers with defects in homologous recombination repair by synthetic lethality. New therapies are needed to reduce recurrence in patients with BRCA1 or BRCA2 germline mutation–associated early breast cancer.
Paper PDF
This paper's license is marked as closed access or non-commercial and cannot be viewed on ResearchHub. Visit the paper's external site.